Insilico and Ageing research at King’s partner for health-span and longevity collaboration
Insilico and Ageing Research at King’s enter a research collaboration to optimize opportunities for healthy ageing and longevity
Wednesday, May 22 – Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, announces its partnership with Ageing Research at King’s (ARK) – dedicated to enhancing multidisciplinary research collaborations across King’s College London and King’s Health Partners to better understand the mechanisms of ageing and improving health-span. The goal of this collaboration is to employ a set of AI-based methods, to explore patterns that have significant potential to impact healthy ageing, age-related diseases and targeted therapeutics.
ARK is uniquely positioned to address the challenges of an ageing world, and to provide answers at multiple levels, from cellular mechanisms to social sciences. ARK will develop a programme of events to facilitate networking in AI research across King’s and to foster research supported by UK Research and Innovation, charities and industrial partners both in the UK and globally. The ARK partnership with Insilico provides an opportunity to deliver academic excellence in AI methods for ageing and longevity research. This will complement the recently launched London Medical Imaging and AI Centre for Value Based Health Care at King’s.
“The applications of modern artificial intelligence algorithms within the field of aging research offer tremendous opportunities. Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and target identification, and I am certain that our set of software tools, deep domain expertise in target identification and medicinal chemistry, and focus on aging and age-related diseases will contribute to the ARK’s initiative and research.” – said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
“ARK is committed to bringing together AI expertise across King’s to explore its utility and impact for healthy ageing. With larger multifactorial repositories of data in ageing research; incorporation of advanced AI methods represents an opportunity to develop novel therapeutic approaches in precision medicine for age-related diseases and to identify strategies for healthy ageing. We are delighted to partner with Insilico Medicine to bring together industry leading AI experts with ARK-associated academics and clinicians, to accelerate ageing and longevity research.” said Richard Siow, Ph.D., Director of ARK and former Vice-Dean (International), Faculty of Life Sciences & Medicine, King’s College London.
For further information, images or interviews, please contact:
Insilico Medicine: Klug Gehilfe email@example.com
Ageing Research at King’s: Chris Albertyn firstname.lastname@example.org
About Ageing Research at King’s (ARK)
ARK is a cross-faculty multidisciplinary consortium of academics and clinicians which brings together scholarship and research in ageing in several complementary areas. ARK represents King’s world class excellence for research on the biology of ageing, from the basic mechanisms in biogerontology to clinical translation and the social impact of ageing. The primary purpose of ARK is to enhance multidisciplinary research collaborations across King’s College London and King’s Health Partners Academic Health Sciences Centre to better understand the mechanisms of ageing and improving health-span. As ageing consists of complex systems at the level of biomedicine, psychology and society, ARK fosters a multidisciplinary approach to better understand the processes involved in ageing and longevity.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D sites and management resources in the US, Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in artificial intelligence for biomarker discovery, target identification, generation of novel chemistry and aging research.
Since 2015 Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/